GenSight Biologics S.A.
GSGTF · OTC
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.02 | -0.01 | 0.01 | -0.05 |
| FCF Yield | -12.07% | -29.16% | -29.77% | -39.38% |
| EV / EBITDA | -7.65 | -8.90 | -5.50 | -3.28 |
| Quality | ||||
| ROIC | 185.40% | -412.86% | -154.55% | -992.79% |
| Gross Margin | 100.00% | 100.00% | 100.00% | 849.47% |
| Cash Conversion Ratio | 0.45 | 0.69 | 1.26 | 0.59 |
| Growth | ||||
| Revenue 3-Year CAGR | -50.87% | -24.09% | -1.64% | 6.35% |
| Free Cash Flow Growth | 43.61% | 23.88% | 13.22% | 48.63% |
| Safety | ||||
| Net Debt / EBITDA | -3.19 | -4.13 | -2.14 | -1.42 |
| Interest Coverage | -3.26 | -13.54 | -7.94 | -6.96 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 1.87 | -0.39 | 1.82 | -191.52 |